Dr. Charles Nenner is back for an exclusive interview, discussing his outlook for the economy.
Spoiler alert: it’s grim – but opportunities abound for savvy investors.
Charles Nenner: Coronavirus TSUNAMI
Newswire
- [ March 25, 2025 ] Predictive Oncology (NASDAQ: POAI) Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary Newsmakers
- [ March 25, 2025 ] Tenon Medical (NASDAQ:TNON) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion Newsmakers
- [ March 24, 2025 ] Damon Inc. (NASDAQ: DMN) Announces Closing of Upsized $16.5 Million Underwritten Public Offering Newsmakers
- [ March 18, 2025 ] ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil CEO Interview
- [ March 17, 2025 ] Hyperfine (NASDAQ: HYPR) and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation Newsmakers
- [ March 13, 2025 ] FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD) Newsmakers
- [ March 13, 2025 ] ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. Newsmakers
- [ March 13, 2025 ] “Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans Aerospace & Defense
- [ March 6, 2025 ] Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer Newsmakers
- [ March 3, 2025 ] BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia Newsmakers
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.